Evaluation of WO2012177707 and WO2012097269: Vertex's phosphate prodrugs of gyrase and topoisomerase antibacterial agents

Author： Finn John  

Publisher： Informa Healthcare

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.23, Iss.9, 2013-09, pp. : 1233-1237

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Boehringer Ingleheim's selective glucocorticoid receptor agonist development candidate: evaluation of WO2010141331, WO2010141332 and WO2010141333

By Norman Peter  

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 7, 2011-07 ,pp. : 1137-1142

Informa Healthcare

Access to resources Recommend Favorite

Discovery and Development of ATPase Inhibitors of DNA Gyrase as Antibacterial Agents

By  

Current Medicinal Chemistry, Vol. 14, Iss. 19, 2007-08 ,pp. : 2033-2047

Bentham Science Publishers

Access to resources Recommend Favorite

Polymyxin derivatives: a patent evaluation (WO2012168820)

By Wu Haifan  

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 8, 2013-08 ,pp. : 1075-1081

Informa Healthcare

Access to resources Recommend Favorite

Targeted antimicrobial moieties (WO2010080819): patent evaluation

By Song Zhong-Cheng   Zhu Hai-Liang  

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 4, 2011-04 ,pp. : 593-600

Informa Healthcare

Access to resources Recommend Favorite

Evaluation of WO2012003387, Gilead's ASK1 inhibitors

By Norman Peter  

Expert Opinion on Therapeutic Patents, Vol. 22, Iss. 4, 2012-04 ,pp. : 455-459

Informa Healthcare

Access to resources Recommend Favorite